Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1989 7
1990 7
1991 4
1992 9
1993 7
1994 6
1995 4
1996 1
1997 6
1998 4
1999 5
2000 11
2001 2
2002 7
2003 7
2004 8
2005 6
2006 6
2007 12
2008 9
2009 9
2010 10
2011 12
2012 8
2013 6
2014 11
2015 4
2016 5
2017 5
2018 7
2019 6
2020 6
2021 9
2022 4
2023 11
2024 6
2025 7
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Results by year

Filters applied: . Clear all
Page 1
Uveal melanoma: In the era of new treatments.
Wespiser M, Neidhardt E, Negrier S. Wespiser M, et al. Among authors: negrier s. Cancer Treat Rev. 2023 Sep;119:102599. doi: 10.1016/j.ctrv.2023.102599. Epub 2023 Jul 7. Cancer Treat Rev. 2023. PMID: 37473516 Review.
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Motzer RJ, et al. Among authors: negrier s. N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779531 Free PMC article. Clinical Trial.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Motzer RJ, et al. Among authors: negrier s. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044. N Engl J Med. 2007. PMID: 17215529 Free article. Clinical Trial.
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.
Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D, Suárez C, Négrier S, Lee JL, Santini D, Bedke J, Staehler M, Kollmannsberger C, Choueiri TK, Motzer RJ, Burgents JE, Xie R, Okpara CE, Powles T. Grünwald V, et al. Among authors: negrier s. Int J Cancer. 2025 Apr 1;156(7):1326-1335. doi: 10.1002/ijc.35288. Epub 2024 Dec 30. Int J Cancer. 2025. PMID: 39739622 Free PMC article. Clinical Trial.
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juárez V, Rini BI, Larkin J, Nolè F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ. Choueiri TK, et al. Among authors: negrier s. Ann Oncol. 2025 Apr;36(4):387-392. doi: 10.1016/j.annonc.2024.12.008. Epub 2024 Dec 18. Ann Oncol. 2025. PMID: 39706335 Free PMC article. Clinical Trial.
Cutaneous melanoma.
Négrier S, Fervers B, Bailly C, Beckendorf V, Cupissol D, Doré JF, Dorval T, Garbay JR, Vilmer C; French National Federation of Cancer (FNCLCC). Négrier S, et al. Br J Cancer. 2001 May;84 Suppl 2(Suppl 2):81-5. doi: 10.1054/bjoc.2001.1771. Br J Cancer. 2001. PMID: 11355977 Free PMC article. No abstract available.
[Kidney tumors].
Méjean A, André M, Doublet JD, Fendler JP, de Fromont M, Hélénon O, Lang H, Négrier S, Patard JJ, Piéchaud T; Comité de Cancérologie de l'Association Française d'Urologie. Méjean A, et al. Among authors: negrier s. Prog Urol. 2004 Nov;14(4 Suppl 1):997, 999-1035. Prog Urol. 2004. PMID: 15779656 Review. French. No abstract available.
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Diab A, Ascierto PA, Maio M, Abdel-Wahab R, Negrier S, Mortier L, Arenberger P, Dalle S, Krajsova I, de la Cruz L, Leccia MT, Guida M, Lebbe C, Grob JJ, Butler MO, In GK, Loquai C, Walker JWT, Atkinson V, Kapiteijn E, Haferkamp S, Chunduru S, Rahimian S, Guidoboni M, Robert C. Diab A, et al. Among authors: negrier s. J Clin Oncol. 2025 May 20;43(15):1800-1809. doi: 10.1200/JCO.24.00727. Epub 2025 Mar 6. J Clin Oncol. 2025. PMID: 40048691 Clinical Trial.
Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT).
Gavira J, Auclin E, Rey-Cardenas M, Roy P, Tapia JC, Nay P, Vinceneux A, Lefort F, Nannini S, Randis AMDC, Naoun N, Escudier B, Borchiellini D, de Velasco G, Barthelemy P, Gross-Goupil M, Negrier S, Oudard S, Frazer RD, Albiges L, Flippot R. Gavira J, et al. Among authors: negrier s. Eur J Cancer. 2025 May 2;220:115389. doi: 10.1016/j.ejca.2025.115389. Epub 2025 Mar 26. Eur J Cancer. 2025. PMID: 40184846
235 results